1-环己基环己烯 | 3282-54-0

• 分子结构分类: 有机化合物 - 碳氢化合物 - 不饱和烃
• 中文名称: 1-环己基环己烯
• 英文名称: 1-cyclohexyl-1-cyclohexene
• 英文别名: 1-Cyclohexyl-cyclohexen-(1)；1-Cyclohexyl-cyclohexen；1-cyclohexylcyclohexene；cyclohexyl-1-cyclohexene；Cyclohexene, 1-cyclohexyl-
• CAS: 3282-54-0
• 化学式: C₁₂H₂₀
• mdl: MFCD00053264
• 分子量: 164.291
• InChiKey: RFFCUDDJJDOFLS-UHFFFAOYSA-N

物化性质

• 熔点：
  -43 °C
• 沸点：
  236-237.5 °C(Press: 755 Torr)
• 密度：
  0.9071 g/cm3(Temp: 19.4 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 海关编码：
  2902199090

反应信息

• 作为反应物：
  描述：

  1-环己基环己烯 在 氯仿 、 氢溴酸 作用下， 生成 1-bromo-bicyclohexyl
  参考文献：
  名称：

  Truffault, Bulletin de la Societe Chimique de France, 1936, vol. <5> 3, p. 442,452

  摘要：

  DOI：
• 作为产物：
  描述：

  环己酚 在 potassium pyrosulfate 、 溶剂黄146 、 铂 作用下， 生成 1-环己基环己烯
  参考文献：
  名称：

  Schrauth; Goerig, Chemische Berichte, 1923, vol. 56, p. 1904

  摘要：

  DOI：

文献信息

• Promising Ni/Al-SBA-15 catalysts for hydrodeoxygenation of dibenzofuran into fuel grade hydrocarbons: synergetic effect of Ni and Al-SBA-15 support
  作者：Sharafadeen Gbadamasi、Tammar Hussein Ali、Lee Hwei Voon、Abdulazeez Yusuf Atta、Putla Sudarsanam、Suresh K. Bhargava、Sharifah Bee Abd Hamid

  DOI：10.1039/c5ra27526a

  日期：——

  has been undertaken with the aim of designing promising noble-metal-free catalysts for efficient hydrodeoxygenation (HDO) of dibenzofuran (DBF) into fuel grade hydrocarbons. For this, various Ni/Al-SBA-15 catalysts with different Si/Al (50, 60, 70 and 80) mole ratios were synthesized and their catalytic performance was tested for HDO of DBF in a batch reactor. The catalysts were systematically characterized

  进行这项工作的目的是设计有前途的无贵金属催化剂，以将二苯并呋喃（DBF）高效加氢脱氧（HDO）转化为燃料级碳氢化合物。为此，合成了具有不同Si / Al（50、60、70和80）摩尔比的各种Ni / Al-SBA-15催化剂，并在间歇反应器中测试了它们的催化性能，以评估DBF的HDO。使用XRD，N 2-吸附-解吸，拉曼，H 2 -TPR，NH 3 -TPD，XRF和FESEM技术对催化剂进行了系统表征。活动结果表明，DBF的HDO通过镍位点上的苯加氢，然后裂解酸性位点上的C-O键，生成不饱和烃。Ni位点上的不饱和烃的进一步氢化得到双环己烷作为主要产物。值得注意的是，除Ni / SBA-15和Ni / Al-SBA-15（80）（Si / Al摩尔比= 80）催化剂外，所有催化剂的DBF转化率均为100％，分别显示97.97％和99.31％ 。在这项研究中注意到的一个重要观察结果是，将Al掺入Ni
• Effective hydrodeoxygenation of dibenzofuran by a bimetallic catalyst in water
  作者：Peng Dong、Guo-ping Lu、Chun Cai

  DOI：10.1039/c5nj02164b

  日期：——

  hydrodeoxygenation (HDO) of dibenzofuran (DBF) catalyzed by a bimetallic nickel/platinum (Ni/Pt) catalyst in water was demonstrated at 200 °C and 1.2 MPa hydrogen (H2) pressure. The bimetallic catalysts prepared by a wet chemical method exhibit prominent activity that overcomes the limitations of use of a single Ni or Pt metal catalyst. The yield of HDO products can be up to 90%. Reaction results indicate

  在200°C和1.2 MPa的氢气（H 2）压力下，证明了由双金属镍/铂（Ni / Pt）催化剂在水中催化的二苯并呋喃（DBF）的有效加氢脱氧（HDO）。通过湿化学方法制备的双金属催化剂显示出显着的活性，克服了使用单一Ni或Pt金属催化剂的局限性。HDO产品的产率可高达90％。反应结果表明DBF的转化率受反应温度和H 2压力的影响。脱氧选择性很大程度上取决于反应温度。还提出了反应途径。
• Highly Selective Formation of Cyclopentanol through Liquid-Phase Cyclopentene Hydration over MCM-22 Catalysts
  作者：Duangamol Nuntasri、Peng Wu、Takashi Tatsumi

  DOI：10.1246/cl.2002.224

  日期：2002.2

  MCM-22 catalyst exhibits an extremely high shape selectivity not observed on other zeolites of MFI, MOR and BEA structures, in that it effectively catalyzes the liquid-phase hydration of cyclopentene at a conversion up to 10% and a cyclopentanol selectivity as high as 99%.

  MCM-22催化剂展现出的形状选择性极高，是其他具有MFI、MOR和BEA结构的分子筛所没有的，它能有效地催化环戊烯的液相水合反应，转化率高达10%，且环戊醇的选择性高达99%。
• Triphosgene and DMAP as Mild Reagents for Chemoselective Dehydration of Tertiary Alcohols
  作者：Moshood O. Ganiu、Alexander H. Cleveland、Jarrod L. Paul、Rendy Kartika

  DOI：10.1021/acs.orglett.9b01959

  日期：2019.7.19

  The utility of triphosgene and DMAP as mild reagents for chemoselective dehydration of tertiary alcohols is reported. Performed in dichloromethane at room temperature, this reaction is readily tolerated by a broad scope of substrates, yielding alkenes preferentially with the (E)-geometry. While formation of the Hofmann products is generally favored, a dramatic change in alkene selectivity toward the

  据报道，三光气和DMAP作为温和试剂用于叔醇的化学选择性脱水。该反应在室温下在二氯甲烷中进行，很容易被宽范围的底物所耐受，优先以（E）-几何结构产生烯烃。尽管通常优选霍夫曼产物的形成，但是当反应在二氯乙烷中在回流下进行时，观察到烯烃对Zaitzev产物的选择性的急剧变化。
• New Insights into the Second Generation Antihistamines
  作者：Garry M. Walsh、Lucio Annunziato、Nelly Frossard、Klaas Knol、Sten Levander、Jean-Marie Nicolas、Maurizo Taglialatela、Michael D. Tharp、Jean P. Tillement、Henk Timmerman

  DOI：10.2165/00003495-200161020-00006

  日期：——

  Second generation antihistamines are recognised as being highly effective treatments for allergy-based disease and are among the most frequently prescribed and safest drugs in the world. However, consideration of the therapeutic index or the benefit/risk ratio of the H1 receptor antagonists is of paramount importance when prescribing this class of compounds as they are used to treat non-life threatening conditions. There are many second generation antihistamines available and at first examination these appear to be comparable in terms of safety and efficacy. However, the newer antihistamines in fact represent ahererogeneous group of compounds, having markedly differing chemical structures, adverse effects, half-life, tissue distribution and metabolism, spectrum of antihistaminic properties, and varying degrees of anti-inflammatory effects. With regard to the latter, there is growing awareness that some of these compounds might represent useful adjunct medications in asthma therapy. In terms of safety issues, the current second generation grouping includes compounds with proven cardiotoxic effects and others with the potential for adverse drug interactions. Moreover, some of the second generation H1 antagonists have given cause for concern regarding their potential to cause a degree of somnolence in some individuals. It can be argued, therefore, that the present second generation grouping is too large and indistinct since this was based primarily on the concept of separating the first generation sedating compounds from nonsedating H1 antagonists. Although it is too early to talk about a third generation grouping of antihistamines, future membership of such a classification could be based on a low volume of distribution coupled with a lack of sedating effects, drug interactions and cardiotoxicity.

  第二代抗组胺药被认为是治疗过敏性疾病的有效药物，并且是全球最常用和最安全的药物之一。然而，在开处方时考虑H1受体拮抗剂的治疗指数或收益/风险比至关重要，因为它们用于治疗非危及生命的疾病。目前有许多第二代抗组胺药可供选择，初步查看其安全性和疗效似乎是相当可比的。然而，较新一代的抗组胺药实际上代表了一组异质化的化合物，具有显著不同的化学结构、不良反应、半衰期、组织分布和代谢、抗组胺特征的谱系，以及不同程度的抗炎效果。关于抗炎效果，越来越多的人意识到这些化合物可能在哮喘治疗中作为有用的辅助药物。在安全性问题方面，目前的第二代抗组胺药中包括一些具有已知心脏毒性影响的药物，以及一些具有潜在不良药物相互作用的药物。此外，一些第二代H1拮抗剂引起了人们对其在某些个体中引起嗜睡的潜在风险的担忧。因此，可以认为目前的第二代药物分组过于庞大且不明确，因为这一分类主要是基于将第一代镇静药物与非镇静H1拮抗剂分开的概念。虽然谈论第三代抗组胺药的分组还为时尚早，但未来这类分类的成员资格可能基于较低的分布量，以及缺乏镇静作用、药物相互作用和心脏毒性。

表征谱图